Saturday, July 11, 2026

Patent directory · USPTO A61K / A61P

Patents matching “inhibitor”

2,878 pharma patents match "inhibitor" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 2,878
Index total 30,257
Page 20 / 120

Quick answer

This filtered view shows 2,878 pharmaceutical patents matching "inhibitor" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

2,878 results for “inhibitor” · 30,257 patents in full index Clear search

  1. US 11518772

    Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors

    NIKANG THERAPEUTICS, INC. · Granted Dec 6, 2022 · Expires Dec 1, 2042

    granted
  2. US 11512309

    Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 29, 2022 · Expires Nov 24, 2042

    granted
  3. US 11504390

    Treatment of increased lipid levels with sterol regulatory element binding transcription factor 1 (SREBF1) inhibitors

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 22, 2022 · Expires Nov 17, 2042

    granted
  4. US 11504364

    Inhibitors of fibroblast activation protein

    PRAXIS BIOTECH LLC · Granted Nov 22, 2022 · Expires Nov 17, 2042

    granted
  5. US 11505600

    Methods of treating skin cancer by administering a PD-1 inhibitor

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 22, 2022 · Expires Nov 17, 2042

    granted
  6. US 11497734

    Dual inhibitors of TIM-3 and PD-1 pathways

    Aurigene Discovery Technologies Limited · Granted Nov 15, 2022 · Expires Nov 10, 2042

    granted
  7. US 11497740

    Use of Jumonji C demethylase inhibitors for the treatment and prevention of chemotherapy resistance and radioresistance in cancer

    The Board of Regents of the University of Texas System · Granted Nov 15, 2022 · Expires Nov 10, 2042

    granted
  8. US 11498928

    Macrocyclic spiroethers as Mcl-1 inhibitors

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Nov 15, 2022 · Expires Nov 10, 2042

    granted
  9. US 11497781

    Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovirus CG0070 and an immune checkpoint inhibitor

    CG ONCOLOGY, INC. · Granted Nov 15, 2022 · Expires Nov 10, 2042

    granted
  10. US 11498905

    Inhibitors of platelet function and methods for use of the same

    The Regents of the University of California · Granted Nov 15, 2022 · Expires Nov 10, 2042

    granted
  11. US 11492351

    MTA-cooperative PRMT5 inhibitors

    Mirati Therapeutics, Inc. · Granted Nov 8, 2022 · Expires Nov 3, 2042

    granted
  12. US 11492349

    IRAK inhibitors and method for making and using

    Rigel Pharmaceuticals, Inc. · Granted Nov 8, 2022 · Expires Nov 3, 2042

    granted
  13. US 11485760

    Inhibitors of CRISPR-Cas9

    The Regents of the University of California · Granted Nov 1, 2022 · Expires Oct 27, 2042

    granted
  14. US 11485739

    Compounds useful as inhibitors of ATR kinase

    Vertex Pharmaceuticals Incorporated · Granted Nov 1, 2022 · Expires Oct 27, 2042

    granted
  15. US 11485788

    Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R inhibitor

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 1, 2022 · Expires Oct 27, 2042

    granted
  16. US 11485738

    Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors

    Mirati Therapeutics, Inc. · Granted Nov 1, 2022 · Expires Oct 27, 2042

    granted
  17. US 11479770

    Use of p38 inhibitors to reduce expression of DUX4

    Fulcrum Therapeutics, Inc. · Granted Oct 25, 2022 · Expires Oct 20, 2042

    granted
  18. US 11479551

    MTA-cooperative PRMT5 inhibitors

    Mirati Therapeutics, Inc. · Granted Oct 25, 2022 · Expires Oct 20, 2042

    granted
  19. US 11479543

    Heterocyclic RIP1 kinase inhibitors

    Rigel Pharmaceuticals, Inc. · Granted Oct 25, 2022 · Expires Oct 20, 2042

    granted
  20. US 11472782

    RIP1 inhibitory compounds and methods for making and using the same

    Rigel Pharmaceuticals, Inc. · Granted Oct 18, 2022 · Expires Oct 13, 2042

    granted
  21. US 11471442

    Administration of gut-selective JAK3 inhibitor

    Theravance Biopharma R&D IP, LLC · Granted Oct 18, 2022 · Expires Oct 13, 2042

    granted
  22. US 11471528

    Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation

    The Government of the United States of America as represented by the Secretary of the Department · Granted Oct 18, 2022 · Expires Oct 13, 2042

    granted
  23. US 11471448

    Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia

    RedHill Biopharma Ltd. · Granted Oct 18, 2022 · Expires Oct 13, 2042

    granted
  24. US 11464856

    Combination therapy using inhibitors of human growth and differentiation factor 15 (GDF-15) and immune checkpoint blockers

    Julius-Maximilians-Universitat Wurzburg · Granted Oct 11, 2022 · Expires Oct 6, 2042

    granted